Biodesix (BDSX) Revenue (2019 - 2026)

Biodesix (BDSX) has 8 years of Revenue data on file, last reported at $25.6 million in Q1 2026.

• Quarterly Revenue rose 42.3% year-over-year to $25.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $96.1 million (up 29.05% YoY) and the FY2025 annual result came in at $88.5 million, up 24.08% from the prior year.
• Revenue declined to $25.6 million in Q1 2026, from $28.8 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $28.8 million in Q4 2025 to a low of $6.5 million in Q1 2022.
• A 5-year average of $16.0 million and a median of $14.8 million in 2024 frame the typical range for Revenue.
• The widest YoY moves for Revenue: up 70.07% in 2022, down 77.32% in 2022.
• Tracing BDSX's Revenue over 5 years: stood at $9.6 million in 2022, then jumped by 52.68% to $14.7 million in 2023, then surged by 39.28% to $20.4 million in 2024, then surged by 40.76% to $28.8 million in 2025, then fell by 11.13% to $25.6 million in 2026.
• The last three Revenue figures came in at $25.6 million (Q1 2026), $28.8 million (Q4 2025), and $21.8 million (Q3 2025), per Business Quant data.